<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048251</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000141</org_study_id>
    <nct_id>NCT05048251</nct_id>
  </id_info>
  <brief_title>Individually Targeted Neuromodulation for Contamination-based OCD</brief_title>
  <official_title>Individually Targeted Neuromodulation for Contamination-based Obsessive-compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types&#xD;
      of obsessions and compulsions. However, current treatments for OCD employ a &quot;one size fits&#xD;
      all&quot; approach and are used for all patients regardless of symptom type. In this project, the&#xD;
      investigators propose to investigate whether a novel method of transcranial magnetic&#xD;
      stimulation specifically reduces contamination/washing symptoms - one of the most common&#xD;
      types of OCD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The symptoms of obsessive-compulsive disorder (OCD) appear linked to dysfunction in a&#xD;
      cortico-striato-thalamo-cortical circuit. However, obsessions and compulsions vary widely&#xD;
      among OCD patients, suggesting that other symptom-specific brain networks may accompany this&#xD;
      core defect. Identifying such networks could lead to personalized treatments, improving upon&#xD;
      current &quot;one size fits all&quot; approaches.&#xD;
&#xD;
      Factor analyses have found distinct symptom dimensions in OCD, but the neural systems&#xD;
      specific to these dimensions remain unclear. Using a novel, data-driven, individual-level&#xD;
      approach to resting-state functional connectivity magnetic resonance imaging (fcMRI), the&#xD;
      investigators have shown that increased connectivity between right medial frontal gyrus (R&#xD;
      MFG) and brain regions within the ventral attention network (VAN) - regions critical to&#xD;
      reorienting attention in response to relevant external stimuli - specifically predicted the&#xD;
      severity of contamination/washing (CONTAM) symptoms, and attenuation of this&#xD;
      hyperconnectivity following treatment was associated with improvement in CONTAM symptoms.&#xD;
      Based on these findings, the investigators hypothesize that decreasing R MFG-VAN connectivity&#xD;
      via transcanial magnetic stimulation (TMS) will normalize attentional reorienting and reduce&#xD;
      CONTAM symptoms in individuals with contamination-based OCD.&#xD;
&#xD;
      The investigators propose a two-phase program to investigate R MFG-targeted TMS as a&#xD;
      potential intervention for contamination-based OCD. First, in the currently study, the&#xD;
      investigators will determine the optimal TMS paradigm to decrease R MFG-VAN connectivity by&#xD;
      administering continuous, intermittent, and sham theta burst stimulation (cTBS, iTBS, sham)&#xD;
      to individuals with contamination-based OCD using a novel individual-level approach to target&#xD;
      the area of R MFG most strongly correlated with VAN based on each participant's pre-treatment&#xD;
      connectivity data. Second, the investigators will use the TMS approach identified in this&#xD;
      study to test the links between reduced R MFG-VAN connectivity, decreased VAN activation&#xD;
      during attentional reorienting, and reduced CONTAM symptoms in a future study using a larger&#xD;
      sample of OCD individuals with CONTAM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional connectivity between R MFG and brain regions within VAN (expressed as a Z-score)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in functional connectivity between: 1) R MFG and right temporoparietal junction (R TPJ); 2) R MFG and left temporoparietal junction (L TPJ); 3) R MFG and right inferior frontal gyrus (R IFG); 4) R MFG and left inferior frontal gyrus (L IFG); 5) R MFG and right anterior insula (R AI); 6) R MFG and left anterior insula (L AI); 7) R MFG and right posteromedial putamen; and 8) R MFG and left posteromedial putamen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional activation of R MFG and brain regions within VAN during an RSVP task (expressed as a beta value)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in activation in: 1) R MFG; 2) R TPJ; 3) L TPJ; 4) R IFG; 5) L IFG; 6) R AI; 7) L AI; 8) R posteromedial putamen; and 9) L posteromedial putamen during visual search on the RSVP task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in score on Category 4 (contamination) on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS) (minimum score: 0 and maximum score: 18; higher scores represent more severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in total score on the Yale-Brown Obsessive Compulsive Scale (YBOCS) (minimum score: 0 and maximum score: 40; higher scores represent more severe symptoms)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>cTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous TBS to right MFG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermittent TBS to right MFG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham stimulation to right MFG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cTBS</intervention_name>
    <description>continuous theta burst stimulation</description>
    <arm_group_label>cTBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTBS</intervention_name>
    <description>intermittent theta burst stimulation</description>
    <arm_group_label>iTBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>sham stimulation</description>
    <arm_group_label>sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female age 18-55 years old&#xD;
&#xD;
          2. DSM-5 diagnosis of OCD as primary presenting disorder&#xD;
&#xD;
          3. CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is&#xD;
             the highest score on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS);&#xD;
             participants with more than one Dimension as highest score will still be eligible as&#xD;
             long as Dimension 4 is one of these)&#xD;
&#xD;
          4. score of â‰¥ 8 on Dimension 4 of the D-YBOCS&#xD;
&#xD;
          5. taking no psychiatric medications or on a stable dose of an SSRI or clomipramine for&#xD;
             at least 8 weeks prior to enrollment. Use of PRN benzodiazepines will be permitted as&#xD;
             long as the dose/usage has not changed significantly leading up to enrollment. No&#xD;
             medication changes will be permitted during the study&#xD;
&#xD;
          6. have not initiated a new course of exposure and response prevention (ERP) therapy&#xD;
             within 8 weeks of enrollment (ongoing ERP will be permitted if initiated more than 8&#xD;
             weeks before enrollment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. positive urine drug screen (other than prescribed benzodiazepines)&#xD;
&#xD;
          2. use of psychiatric medications other than permitted above&#xD;
&#xD;
          3. substance use disorder in the last 3 months (with the exception of nicotine)&#xD;
&#xD;
          4. history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and&#xD;
             past history of depressive, anxiety, and eating disorders permitted as long as OCD is&#xD;
             considered the primary disorder)&#xD;
&#xD;
          5. active suicidal ideation over the week prior to screening (as indicated by answering&#xD;
             yes to questions 1 or 2 on the C-SSRS)&#xD;
&#xD;
          6. history of traumatic brain injury, seizure disorder, neurodegenerative disease, or&#xD;
             other organic brain disease&#xD;
&#xD;
          7. pregnancy or lactating&#xD;
&#xD;
          8. contraindication to MRI scanning or TMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian P Brennan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiana Schnabel</last_name>
    <phone>617-855-2911</phone>
    <email>jschnabel@mclean.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brian P Brennan, MD</last_name>
      <phone>617-855-2911</phone>
      <email>bbrennan@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Brian P. Brennan, MD</investigator_full_name>
    <investigator_title>Medical Director, Obsessive-Compulsive Disorder Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

